Active Genetics & Molecular Biology Cancer

T-max: maximising insights from severe combined immunodeficiency and related disorders

In plain English

AI plain-English summary

Around one in ten babies born with severe combined immunodeficiency (SCID) have no identifiable genetic cause, even after full genome sequencing. This matters because SCID—a condition where infants lack crucial T cells—is fatal without treatment. Newborn screening now catches many cases early, but without knowing the exact faulty gene, doctors cannot tailor treatments, predict risks for future siblings, or develop targeted therapies like gene therapy or enzyme replacement. The research aims to close this diagnostic gap by finding the hidden genetic causes in two ways: first, by scanning previously overlooked regions of DNA around known SCID genes that might silence them; second, by identifying entirely new genes never before linked to T-cell failure. If successful, this work will give families a definitive genetic diagnosis for currently unexplained SCID cases. It will also deepen fundamental understanding of how T cells develop—knowledge that could eventually lead to new treatments that restore immunity without a stem cell transplant. While the immediate impact is on medical diagnostics and genetic counselling, the fundamental insights into T-cell biology could, over time, inform therapies for other immune disorders or even cancer immunotherapy.

View original technical description
T lymphocytes (T cells) are a special type of white blood cell that is crucial to the human immune system. We know this partly because babies who are unlucky enough to be born without T cells get terribly sick with infections that barely affect healthy children. This very rare condition, called severe combined immunodeficiency ("SCID"), used to be a death sentence until the development of bone marrow transplantation from the late 1960s onwards. Nowadays, stem cell transplantation can save most of these children, as long as their condition is recognised before infection takes hold. For this reason, we now are starting to screen newborn babies for SCID using a test carried out alongside other screens on the dried blood spot already collected at a week of age. If T cell numbers are low, babies undergo further testing and treatment to protect them from infection until the immune system can be put right. Usually, being born with low levels of T cells happens because of spelling mistakes in one of our genes. Genes, which are made of DNA, provide the instructions to make individual proteins. In SCID, mistakes in a single gene mean that T cells are missing a protein they can't do without. As a result, the T cells can't develop properly, leaving the immune system depleted. Scientists have worked out a lot about how healthy T cells develop from studying the many ways this process can go wrong. It turns out that spelling mistakes in many different genes can prevent T cells from developing. This is partly because T cells develop in such a remarkable way! It can be very helpful to know exactly which gene has gone wrong to cause a new case of SCID. It guides the way a patient is treated and furthermore, makes it possible to predict the risk to future pregnancies within the family. Sometimes scientists have been able to design ways of replacing the missing part without a stem cell transplant, for instance by gene therapy or enzyme replacement in some cases. These types of clever treatment rely on knowing exactly which gene has gone wrong, since that is the one that needs to be replaced. It's frustrating then that around 1 in 10 cases of SCID can't be explained genetically, even using the very modern technique of genome sequencing. In this research project, we will try to get to the bottom of why T cell development fails there and what we might be able to do about it. Some of these patients might have new sorts of spelling mistakes in "old" SCID genes, perhaps hidden in parts of the DNA that have the power to turn off neighbouring genes. To give us a better chance of finding these we will look more widely around each SCID gene using new and powerful ways of reading along DNA molecules, and check whether genes are turned on or off in patient's bone marrow cells. Other patients will have spelling mistakes in new genes that haven't been linked to SCID before - they aren't on any textbook list. We have already found some strong candidates by screening for spelling mistakes in past patients with SCID. We have more work to do to understand why the affected genes are so important for T cells, because they are active in lots of other tissues too. To help, we will study each spelling mistake in cells in the test tube, and find out how it disturbs the structure and function of the related protein. We also will study whether the same spelling mistakes in the same genes can cause the mouse version of SCID. If we can be sure of these things, we will have learned something new and important about how T cells work. We should be in a better position to diagnose the same sort of SCID in future babies and provide answers to their mums and dads. We and others will be working hard to find new and better ways to rescue T cell development without a stem cell transplant.

View the original record at the funder ↗

Researchers

Alexandra Kreins (Co-Investigator)Ana Viñuela (Co-Investigator)Austen Worth (Co-Investigator)Joris Veltman (Co-Investigator)Kevin Marchbank (Co-Investigator)Sophie Hambleton (Principal Investigator)Wyatt Yue (Co-Investigator)

Related Research

Grants with similar aims, by meaning.

20IC24 - Gene Editing in Primary Immunodeficiency
Improving the outcome of children with congenital athymia.
Next generation T cell gene therapies for children with leukaemia and immunodeficiency
DevelopIng Genetic medicines for Severe Combined Immunodeficiency (SCID)
17IC26 - Gene Editing in X-Linked Agammaglobulinaemia

Original classification

Research Grant

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.